Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

Ekberg and colleagues proposed that in type 1 diabetes a deficiency of C peptide, a subunit of the proinsulin molecule, also contributes to nerve damage; their animal studies showed that C-peptide ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Sana Biotechnology’s innovative approach to treating type 1 diabetes centers around its HIP-modified pancreatic islet cell transplant. In the context of type 1 diabetes, the body’s immune system ...

Sana Biotechnology (SANA) announced initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic ...

The aim of this study was to compare the results of the C-peptide response to mixed-meal stimulation in LADA patients with different disease durations and subjects with type 2 and adult-onset type ...

Lucknow: Contrary to the popular belief that black coffee and green team contract blood sugar and improve insulin sensitivity ...

The c-peptide result for Baby L was higher at 264 picomoles per litre, which is well within the range expected for a healthy ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...